Despite widespread use of an anti-EGFR monoclonal antibody to prepare tumor-targeted NPs, its large molecular weight and size, limits the penetration of this monoclonal antibody into the tumor microenvironment (Nida et al., 2005; Wu et al., 2006; Melancon et al., 2008; Patra et al., 2008; Yang et al., 2008; Peng et al., 2011). The gene discussed is EGFR; the disease is neoplasm.